MUC5AC Expression in Various Tumor Types and Nonneoplastic Tissue: A Tissue Microarray Study on 10 399 Tissue Samples
Standard
MUC5AC Expression in Various Tumor Types and Nonneoplastic Tissue: A Tissue Microarray Study on 10 399 Tissue Samples. / Rico, Sebastian Dwertmann; Mahnken, Moritz; Büscheck, Franziska; Dum, David; Luebke, Andreas M; Kluth, Martina; Hube-Magg, Claudia; Hinsch, Andrea; Höflmayer, Doris; Möller-Koop, Christina; Fraune, Christoph; Möller, Katharina; Menz, Anne; Bernreuther, Christian; Jacobsen, Frank; Lebok, Patrick; Clauditz, Till S; Sauter, Guido; Uhlig, Ria; Wilczak, Waldemar; Simon, Ronald; Steurer, Stefan; Minner, Sarah; Burandt, Eike; Krech, Till; Marx, Andreas H.
in: TECHNOL CANCER RES T, Jahrgang 20, 15330338211043328, 23.09.2021.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - MUC5AC Expression in Various Tumor Types and Nonneoplastic Tissue: A Tissue Microarray Study on 10 399 Tissue Samples
AU - Rico, Sebastian Dwertmann
AU - Mahnken, Moritz
AU - Büscheck, Franziska
AU - Dum, David
AU - Luebke, Andreas M
AU - Kluth, Martina
AU - Hube-Magg, Claudia
AU - Hinsch, Andrea
AU - Höflmayer, Doris
AU - Möller-Koop, Christina
AU - Fraune, Christoph
AU - Möller, Katharina
AU - Menz, Anne
AU - Bernreuther, Christian
AU - Jacobsen, Frank
AU - Lebok, Patrick
AU - Clauditz, Till S
AU - Sauter, Guido
AU - Uhlig, Ria
AU - Wilczak, Waldemar
AU - Simon, Ronald
AU - Steurer, Stefan
AU - Minner, Sarah
AU - Burandt, Eike
AU - Krech, Till
AU - Marx, Andreas H
PY - 2021/9/23
Y1 - 2021/9/23
N2 - Background: Mucin 5AC (MUC5AC) belongs to the glycoprotein family of secreted gel-forming mucins and is physiologically expressed in some epithelial cells. Studies have shown that MUC5AC is also expressed in several cancer types suggesting a potential utility for the distinction of tumor types and subtypes. Methods: To systematically determine MUC5AC expression in normal and cancerous tissues, a tissue microarray containing 10 399 samples from 111 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry. Results: MUC5AC was expressed in normal mucus-producing cells of various organs. At least weak MUC5AC positivity was seen in 44 of 111 (40%) tumor entities. Of these 44 tumor entities, 28 included also tumors with strong positivity. MUC5AC immunostaining was most commonly seen in esophageal adenocarcinoma (72%), colon adenoma (62%), ductal adenocarcinoma of the pancreas (64%), mucinous carcinoma of the ovary (46%), diffuse gastric adenocarcinoma (44%), pancreatic ampullary adenocarcinoma (41%), intestinal gastric adenocarcinoma (39%), and bronchioloalveolar carcinoma (33%). Clinically relevant tumors with complete or almost complete absence of MUC5AC staining included small cell carcinoma of the lung (0% of 17), clear cell renal cell carcinoma (0% of 507), papillary thyroid carcinoma (0% of 359), breast cancer (2% of 1097), prostate cancer (2% of 228), soft tissue tumors (0.1% of 968), and hematological neoplasias (0% of 111). Conclusion: The highly standardized analysis of a broad range of cancers identified a ranking order of tumors according to their relative prevalence of MUC5AC expression.
AB - Background: Mucin 5AC (MUC5AC) belongs to the glycoprotein family of secreted gel-forming mucins and is physiologically expressed in some epithelial cells. Studies have shown that MUC5AC is also expressed in several cancer types suggesting a potential utility for the distinction of tumor types and subtypes. Methods: To systematically determine MUC5AC expression in normal and cancerous tissues, a tissue microarray containing 10 399 samples from 111 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry. Results: MUC5AC was expressed in normal mucus-producing cells of various organs. At least weak MUC5AC positivity was seen in 44 of 111 (40%) tumor entities. Of these 44 tumor entities, 28 included also tumors with strong positivity. MUC5AC immunostaining was most commonly seen in esophageal adenocarcinoma (72%), colon adenoma (62%), ductal adenocarcinoma of the pancreas (64%), mucinous carcinoma of the ovary (46%), diffuse gastric adenocarcinoma (44%), pancreatic ampullary adenocarcinoma (41%), intestinal gastric adenocarcinoma (39%), and bronchioloalveolar carcinoma (33%). Clinically relevant tumors with complete or almost complete absence of MUC5AC staining included small cell carcinoma of the lung (0% of 17), clear cell renal cell carcinoma (0% of 507), papillary thyroid carcinoma (0% of 359), breast cancer (2% of 1097), prostate cancer (2% of 228), soft tissue tumors (0.1% of 968), and hematological neoplasias (0% of 111). Conclusion: The highly standardized analysis of a broad range of cancers identified a ranking order of tumors according to their relative prevalence of MUC5AC expression.
U2 - 10.1177/15330338211043328
DO - 10.1177/15330338211043328
M3 - SCORING: Journal article
C2 - 34547930
VL - 20
JO - TECHNOL CANCER RES T
JF - TECHNOL CANCER RES T
SN - 1533-0346
M1 - 15330338211043328
ER -